Astec Lifesciences’ board has approved the proposal to raise funds through issuance of Non-Convertible Debentures (NCD) for expansion and development of business operations of the Company and meeting the short term and long-term financial requirements of the Company, including but not limited to, expenditure proposed to be incurred for improving the facilities being provided in its set-up and / or meeting the working capital requirements, for an amount upto Rs 50 crore. The Board of Directors of the Company, at its Meeting held on January 30, 2023 has approved the same.
Astec Lifesciences manufactures a wide range of agrochemicals and pharmaceutical intermediates.
